Due to the Covid-19 outbreak, we regret that we cannot currently accept samples for sequencing in Liverpool or Edinburgh, or provide access to our visitor facility in Sheffield. But we will continue to discuss proposed applications and to support our users in the analysis and interpretation of their data. Future users wishing to apply to the facility, including NERC-funded investigators who have requested access to NBAF, can still submit their application forms. We will process applications and, where these are approved, we will organise access to the Facility when we reopen. In the meantime, we are assisting studies of Covid-19.
The NERC Biomolecular Analysis Facility provides access to high-level genomics, metabolomics and bioinformatics provision through its four nodes. NBAF offers the very latest, class-leading technologies, including next-generation sequencing (Illumina and Pacific Biosciences), SNP genotyping, and high resolution MS and NMR metabolomic platforms. Applications include de novo sequencing, metagenomics, epigenetics, sequence-capture, sequencing-based genotyping and expression profiling (RNAseq, oligoarrays and NanoString). NBAF also supports metabolomics, medium-scale genotyping, bioinformatics and advanced data analysis techniques (genome and transcriptome assembly and annotation, expression analysis, etc.).
In 2018-19 NBAF serviced 107 projects, including 59 NERC grants, ran 20 courses, supported 225 academics and 36 students; NBAF published 63 refereed articles in 2018 alone.
If you are eligible to apply to NERC, you are eligible to access NBAF. NBAF supports projects which are not necessarily NERC-funded, although they must fall within NERC’s remit. We are also happy to help with your application to NERC if your project will benefit from access to NBAF. Here’s how to contact us.
NBAF is funded by the UK Natural Environment Research Council (NERC) and is supported by NERC Services and Facilities. You can read a copy of last year’s Facility Annual Report (2018-19) here: NBAF Annual Report 2018-19.